SI-Bone Inc (SIBN)
NASDAQ:SIBN
Want to see SIBN full AI Analyst Report?
SIBN Stock Chart & Stats
$14.09
$0.02(0.14%)
At close: 4:00 PM EST
$14.09
$0.02(0.14%)
Day’s Range― - ―
52-Week Range$11.48 - $21.89
Previous CloseN/A
Volume50.81K
Average Volume (3M)648.60K
Market Cap
$702.49M
Enterprise Value$648.37M
Total Cash (Recent Filing)$144.68M
Total Debt (Recent Filing)$7.35M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Aug 10, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding44,349,280
10 Day Avg. Volume524,959
30 Day Avg. Volume648,599
Financial Highlights & Ratios
PEG Ratio1.08
Price to Book (P/B)4.83
Price to Sales (P/S)4.27
P/FCF Ratio-94.40
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue3.14
Enterprise Value/Gross Profit3.95
Enterprise Value/Ebitda-108.26
Forecast
1Y Price Target
$23.00Price Target Upside63.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.51
Revenue Forecast (FY)$230.50M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsConsistent ~79–80% gross margins deliver durable unit economics, allowing SI‑Bone to absorb modest ASP/mix shifts while funding commercialization and R&D. High margins give operating leverage as procedure volumes expand, materially improving the path to sustained profitability over quarters.
Low Leverage / Solid Balance SheetVery low leverage and a strong equity base provide financial flexibility to fund product launches, partner rollouts and necessary CapEx without near-term debt pressure. This reduces refinancing and dilution risk and supports multi-quarter investment in growth initiatives.
Durable Commercial Adoption & Physician GrowthSustained physician adoption and rising territory productivity indicate scalable commercial traction. A growing installed base and consistent territory performance create durable procedure volume growth that supports repeat implant sales, making revenue expansion less reliant on one-off events.
Bears Say
GAAP Losses And Negative Free Cash FlowOngoing GAAP losses and negative FCF mean the business still consumes cash despite improving margins and EBITDA. Until free cash flow turns sustainably positive, the company may need to manage spending, draw on liquidity, or raise capital — constraining optionality and increasing funding risk over coming quarters.
Near-term CapEx And Cash VariabilityPlanned HQ buildout and elevated instrument/tray CapEx will pressure cash flow and create timing swings in 2–6 months. These necessary investments can delay free cash flow breakeven and force prioritization between launches, commercialization spend, and working-capital needs.
Execution/timing Risk On Partner And Launch RolloutsThe company’s near-term growth depends on phased partner rollouts, training, hospital approvals and seasonal trauma volume. Delays or slower-than-expected adoption by partners or hospitals would push revenue out, reduce anticipated operating leverage, and keep profitability improvements backloaded.
SI-Bone News
SIBN FAQ
What was SI-Bone Inc’s price range in the past 12 months?
SI-Bone Inc lowest stock price was $11.48 and its highest was $21.89 in the past 12 months.
What is SI-Bone Inc’s market cap?
SI-Bone Inc’s market cap is $702.49M.
When is SI-Bone Inc’s upcoming earnings report date?
SI-Bone Inc’s upcoming earnings report date is Aug 10, 2026 which is in 49 days.
How were SI-Bone Inc’s earnings last quarter?
SI-Bone Inc released its earnings results on May 11, 2026. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.188 by $0.088.
Is SI-Bone Inc overvalued?
According to Wall Street analysts SI-Bone Inc’s price is currently Undervalued.
Does SI-Bone Inc pay dividends?
SI-Bone Inc does not currently pay dividends.
What is SI-Bone Inc’s EPS estimate?
SI-Bone Inc’s EPS estimate is -0.15.
How many shares outstanding does SI-Bone Inc have?
SI-Bone Inc has 44,349,280 shares outstanding.
What happened to SI-Bone Inc’s price movement after its last earnings report?
SI-Bone Inc reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.188. Following the earnings report the stock price went up 19.724%.
Which hedge fund is a major shareholder of SI-Bone Inc?
Currently, no hedge funds are holding shares in SIBN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SI-Bone Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.00 (63.24% Upside)
$23.00 (63.24% Upside)
Blogger Sentiment
Bullish
SIBN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 741.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $482.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
54.93%
12-Months-Change
Fundamentals
Return on Equity
-9.56%
Trailing 12-Months
Asset Growth
6.79%
Trailing 12-Months
Company Description
SI-Bone Inc
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.
SIBN Company Deck
SIBN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial and financial momentum: double-digit top-line growth, industry-leading gross margins (~79.8%), improving profitability (Adjusted EBITDA up >440%), record physician engagement, multiple product launches, and a meaningful potential reimbursement tailwind from proposed CMS DRG changes. These positives are balanced by remaining GAAP net losses, negative free cash flow (though improved), near-term cash flow variability from HQ buildout and CapEx, and execution/timing risks around partner rollouts and ASP mix pressure. On balance, the strength in growth, margins, guidance raise, product pipeline, and reimbursement outlook outweigh the execution and timing headwinds.View all SIBN earnings summariesSIBN Stock 12 Month Forecast
Average Price Target
$23.00
▲(63.24% Upside)
Technical Analysis
Ownership Overview
5.17% Insiders
26.01% Mutual Funds
46.01% Other Institutional Investors
12.00% Public Companies and
Individual Investors